Showing 1711-1720 of 2314 results for "".
- DORC Unveils Enhancements to the EVA Phacovitrectomy Systemhttps://modernod.com/news/dorc-unveils-enhancements-to-the-eva-phacovitrectomy-system/2476178/DORC has announced the launch several enhancements to its EVA surgical system aimed at delivering both operating room efficiency and surgical performance. The enhancements include a new EVA footswitch that been completely redesigned. Control of the EVA endolaser is now integrated into the
- Aerpio Pharmaceuticals Completes Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-completes-patient-dosing-in-time-2b-study-of-akb-9778-in-diabetic-retinopathy/2476181/Aerpio Pharmaceuticals announced the completion of patient dosing in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe nonproliferative diabetic retinopathy (NPDR). &#
- EMA Handed Down Fewer Positive Drug Opinions in 2018https://modernod.com/news/ema-handed-down-fewer-positive-drug-opinions-in-2018/2476203/In 2018, the European Medicines Agency (EMA) recommended marketing authorization for 84 new medicines, down from 92 in 2017, according to a report in Medscape. The 84 medicines given a thumbs up by EMA’s Committee for Medicin
- Dompé Announces First Treatment with Oxervate Eye Drops for Neurotrophic Keratitis (NK)https://modernod.com/news/dompe-announces-first-treatment-with-oxervate-eye-drops-for-neurotrophic-keratitis-nk/2476224/Dompé announced the first treatment of a patient with Oxervate eye drops (cenegermin-bkbj) in the United States. Oxervate was approved by the FDA in August 2018 as the first drug specifically indicated to treat neurotrophic keratitis
- Akorn CEO Steps Down After Loss of $4.3 Billion Fresenius Dealhttps://modernod.com/news/akorn-ceo-steps-down-after-loss-of-4-3-billion-fresenius-deal/2476150/Akorn’s CEO stepped down after the Delaware Supreme Court ruled that a rapid downturn in its business was grounds for Fresenius SE to walk away from a $4.3 billion buyout of the generic drugmaker, according to a Bloomberg News
- Silgan Dispensing Introduces Iridya Eye Dropper to Ensure Accurate Doses Down to the Drophttps://modernod.com/news/silgan-dispensing-introduces-iridya-eye-dropper-to-ensure-accurate-doses-down-to-the-drop/2479804/Silgan Dispensing has launched Iridya, a next-generation, multi-dose preservative-free eye dropper. The Iridya eye dropper ensures consumers an accurate dose and an easy-to-use design, while also providing safe delivery of ophthalmic medication. Its elongated tip provides greater accuracy when di
- High Dose of Sildenafil Tied to Long-term Retinal Damage in Case Reporthttps://modernod.com/news/high-dose-of-sildenafil-tied-to-long-term-retinal-damage-in-case-report/2479814/A patient who took a high dose of the erectile dysfunction drug sildenafil citrate developed long-term, and possibly irreversible, retinal damage with bilateral multicolored photopsia (perceived flashes of light) and erythropsia (red-tinted vision), according to a
- Regenxbio Completes Dosing of Fourth Cohort in Phase 1 Trial of RGX-314 Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-dosing-of-fourth-cohort-in-phase-1-trial-of-rgx-314-gene-therapy-for-wet-amd/2479815/Regenxbio announced it has completed dosing of the fourth cohort of six patients in a phase 1 clinical trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (AMD). A total of 24 subjects have been dosed in the trial. The company also announced that an updated summary
- Donna Fishman Named Director of the National Center for Children’s Vision and Eye Health at Prevent Blindnesshttps://modernod.com/news/donna-fishman-named-director-of-the-national-center-for-childrens-vision-and-eye-health-at-prevent-blindness/2479823/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has named Donna Fishman, MPH, as Director. In her new role, she will provide technical assistance to federal and state agencies, as well as national organizations, on system reform strategies that involve child
- Apellis Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophyhttps://modernod.com/news/apellis-announces-first-patient-dosed-in-its-phase-3-clinical-program-for-apl-2-in-patients-with-geographic-atrophy/2479898/Apellis Pharmaceuticals announced that it has commenced its phase 3 clinical program for APL-2 in patients with geographic atrophy (GA), consisting of two phase 3 trials (DERBY & OAKS.) The first patient has been dosed in the OAKS trial and the first patient has been enrolled in the